Drug Trial Radar · NCT04072952
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219
Actual
Start
Sep 22, 2019
Primary completion
Sep 13, 2024
Study completion Mar 5, 2026
Sponsor
- Lead sponsor
- Arvinas Estrogen Receptor, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Aug 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 1/2 dose escalation and cohort expansion study and assessed the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or mBC, who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Conditions
- Breast Cancer
Interventions
VepdegestrantDrug
Vepdegestrant administered QD for 28-day cycles
VepdegestrantDrug
Vepdegestrant administered QD or BID for 28-day cycles.
PalbociclibDrug
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of TreatmentTime frame: Baseline (Day 1) up to C1D28
- Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
- Part B: Clinical Benefit Rate (CBR)Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
- Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of TreatmentTime frame: Baseline (Day 1) up to C1D28
- Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
- Part C: Maximum Tolerated Dose (MTD)Time frame: Baseline (Day 1) up to C1D28
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Palo Alto, California
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Santa Monica, California
Clinical Trial Site
Norwalk, Connecticut
Clinical Trial Site
Fort Myers, Florida
Clinical Trial Site
Tampa, Florida
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Ann Arbor, Michigan
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
East Brunswick, New Jersey
Clinical Trial Site
The Bronx, New York
Clinical Trial Site
Charlotte, North Carolina
Clinical Trial Site
Nashville, Tennessee
Clinical Trial Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.